- Cancer Types
Information about risk, prevention, screening, symptoms, diagnosis, treatment, and support for all cancers Cancer A to Z - Cancer Treatment
Cancer Treatment
Information about cancer treatment, including surgery, chemotherapy, radiation therapy, clinical trials, proton therapy, complementary medicine, and cutting edge technologies.
- Risk and Prevention
- Cancer Drugs
- Support
Support
Ways for cancer patients and caregivers to cope with cancer, side effects, nutrition, general cancer support issues, grief/end of life issues, and shared survivor's experiences.
- Healthcare Professionals
- Clinical Trials
My Patient Treatment Binder
OncoLink Blogs
What's My Cancer Risk?
OncoPilot: Navigating Your Cancer Journey
Community Events Calendar
OncoLink eNews
Abramson Cancer CenterMonday, June 4 , 2007
OncoLink reporters provide in-depth coverage of scientific presentations from the 43rd Annual ASCO Meeting.
|
A randomized trial of prophylactic cranial irradiation (PCI) versus no PCI in extensive disease small cell lung cancer after a response to chemotherapy (EORTC 08993-22993)
Presenter: Bernard SlotmanPresenter's Affiliation: EORTC Radiation Oncology and Lung Cancer GroupsType of Session: PlenaryBackground At diagnosis, patients with small cell lung cancer have a high rate of brain metastasis (around 20%) and this... |
|
|
A randomized trial of prophylactic cranial irradiation (PCI) versus no PCI in extensive disease small cell lung cancer after a response to chemotherapy (EORTC 08993-22993)
Presenter: Bernard SlotmanPresenter's Affiliation: EORTC Radiation Oncology and Lung Cancer GroupsType of Session: PlenaryBackground At diagnosis, patients with small cell lung cancer have a high rate of brain metastasis (around 20%) and this... |
|
|
A randomized trial of prophylactic cranial irradiation (PCI) versus no PCI in extensive disease small cell lung cancer after a response to chemotherapy (EORTC 08993-22993)
Scientific Session: A randomized trial of prophylactic cranial irradiation (PCI) versus no PCI in extensive disease small cell lung cancer after a response to chemotherapy (EORTC 08993-22993) At diagnosis, patients with small cell lung cancer... |
|
|
A randomized, controlled, double-blind phase III study (AVOREN) of bevacizumab/interferon-a2a vs. placebo/interferon-a2a as first-line therapy in metastatic renal cell carcinoma
Presenter: Bernard EscudierPresenter's Affiliation: Institut Gustave Roussy, Villejuif, FranceType of Session: PlenaryBackground Until recently, treatment of metastatic renal cell carcinoma (RCC) included immunotherapy as the standard of care. ... |
|
|
A randomized, controlled, double-blind phase III study (AVOREN) of bevacizumab/interferon-a2a vs. placebo/interferon-a2a as first-line therapy in metastatic renal cell carcinoma
Scientific Session: A randomized, controlled, double-blind phase III study (AVOREN) of bevacizumab/interferon-a2a vs. placebo/interferon-a2a as first-line therapy in metastatic renal cell carcinoma This was a phase III, randomized study for... |
|
|
Cigarette smoking during irinotecan therapy: Effects on pharmacokinetics and neutropenia
Presenter: De Jong, F.A.Presenter's Affiliation: Erasmus University Medical Center, Rotterdam, the NetherlandsType of Session: ScientificBackground Irinotectan is known for its broad spectrum of anti-tumor activity and its narrow therapeutic... |
|
|
Cigarette smoking during irinotecan therapy: Effects on pharmacokinetics and neutropenia
Presenter: De Jong, F.A.Presenter's Affiliation: Erasmus University Medical Center, Rotterdam, the NetherlandsType of Session: ScientificBackground Irinotectan is known for its broad spectrum of anti-tumor activity and its narrow therapeutic... |
|
|
Cigarette smoking during irinotecan therapy: Effects on pharmacokinetics and neutropenia
Scientific Session: Cigarette smoking during irinotecan therapy: Effects on pharmacokinetics and neutropenia Cytochrome P450 enzymes in the liver are important for the detoxification of many drugs and substances. Exposure to cigarette smoke can... |
|
|
Concomitant and adjuvant androgen deprivation (ADT) with external beam irradiation (RT) for locally advanced prostate cancer: 6 months versus 3 years ADT--Results of the randomized EORTC Phase III trial 22961
Presenter: M. BollaPresenter's Affiliation: Centre Hospitalier Regional de Grenoble, Grenoble, FranceType of Session: ScientificBackground The optimal duration of hormone therapy for locally advanced prostate cancer remains controversial. Since... |
|
|
Concomitant and adjuvant androgen deprivation (ADT) with external beam irradiation (RT) for locally advanced prostate cancer: 6 months versus 3 years ADT--Results of the randomized EORTC Phase III trial 22961
Scientific Session: Concomitant and adjuvant androgen deprivation (ADT) with external beam irradiation (RT) for locally advanced prostate cancer: 6 months versus 3 years ADT--Results of the randomized EORTC Phase III trial 22961 The optimal... |
|
|
Diurnal rhythms (DR) in gene expression in human oral mucosa: Implications for gender differences in toxicity, response and survival and optimal timing of targeted therapy (Rx)
Presenter: Bjarnason, G.A.Presenter's Affiliation: Toronto-Sunnybrook Regional Cancer Center, Toronto, ON, Canada.Type of Session: ScientificBackground Diurnal rhythms (DR) have been suggested to be implicated in tumor growth and response to... |
|
|
Effect of consolidation with arsenic trioxide (As2O3) on event-free survival (EFS) and overall survival (OS) among patients with newly diagnosed acute promyelocytic leukemia (APL): North American Intergroup Protocol C9710
Presenter: B. L. PowellPresenter's Affiliation: Wake Forest UniversityType of Session: PlenaryBackground Acute promyelocytic leukemia (APL) was originally described in 1957. APL is defined by a fusion gene unique to this disease, which most... |
|
|
Effect of consolidation with arsenic trioxide (As2O3) on event-free survival (EFS) and overall survival (OS) among patients with newly diagnosed acute promyelocytic leukemia (APL): North American Intergroup Protocol C9710
Scientific Session: Effect of consolidation with arsenic trioxide (As2O3) on event-free survival (EFS) and overall survival (OS) among patients with newly diagnosed acute promyelocytic leukemia (APL): North American Intergroup Protocol C9710 Acute... |
|
|
Final results of the EORTC Intergroup randomized phase III study 40983 [EPOC] evaluating the benefit of peri-operative FOLFOX4 chemotherapy for patients with potentially resectable colorectal cancer liver metastases
Presenter: Bernard NordlingerPresenter's Affiliation: Hospital Ambroise Pare, Boulogne Cedex, FranceType of Session: PlenaryBackground Liver metastases are observed in 40 to 50% of patients with newly diagnosed colorectal cancer worldwide. ... |
|
|
Final results of the EORTC Intergroup randomized phase III study 40983 [EPOC] evaluating the benefit of peri-operative FOLFOX4 chemotherapy for patients with potentially resectable colorectal cancer liver metastases
Presenter: Bernard NordlingerPresenter's Affiliation: Hospital Ambroise Pare, Boulogne Cedex, FranceType of Session: PlenaryBackground Liver metastases are observed in 40 to 50% of patients with newly diagnosed colorectal cancer worldwide. ... |
|
|
Randomized phase III trial of sorafenib versus placebo in patients with advanced hepatocellular carcinoma (HCC)
Presenter: Llovet, J.Presenter's Affiliation: Mount Sinai School of Medicine, New York, NYType of Session: PlenaryBackground Hepatocellular carcinoma (HCC) represents the 5th most common cancer across the globe. Over 600,000 new cases are... |
|
|
Randomized phase III trial of sorafenib versus placebo in patients with advanced hepatocellular carcinoma (HCC)
Presenter: Llovet, J.Presenter's Affiliation: Mount Sinai School of Medicine, New York, NYType of Session: PlenaryBackground Hepatocellular carcinoma (HCC) represents the 5th most common cancer across the globe. Over 600,000 new cases are... |
|
|
Satraplatin (S) demonstrates significant clinical benefits for the treatment of patients with HRPC: Results of a randomized phase III trial.
Presenter: C. N. SternbergPresenter's Affiliation: San Camillo Forlanini Hospital, Rome, ItalyType of Session: ScientificBackground Previously there had only been a limited role for chemotherapy in the treatment of prostate cancer. In... |
Cancer Types
Bone Cancer
Brain Tumors
Breast Cancer
Carcinoid Tumors
Endocrine System Cancers
Gastrointestinal Cancers
Gynecologic Cancers
Head and Neck Cancers
Leukemia
Lung Cancers
Lymphomas
Myelomas
Pediatric Cancers
Penile Cancer
Prostate Cancer
Sarcomas
Skin Cancers
Testicular Cancer
Thyroid Cancer
Urinary Tract Cancers
OncoLink Vet
Cancer Treatment
Biologic Therapy
Bone Marrow Transplants
Chemotherapy
Clinical Trials
Complementary Medicine
Gene Therapy
General Treatment Concerns
Hormone Therapy
PDT Center
Proton Therapy
Radiation Oncology
Surgical Oncology
Targeted Therapies
Vaccine Therapies
Cancer Support
Caregivers
Hospice Care and Bereavement
Nutrition and Cancer
Sexuality & Fertility
Side Effects
Support
Survivorship
Exercise and Cancer
Cancer Resources
Cancer News
OncoLink University
Nurses' Notes
Conferences
Newly Diagnosed Patients
Causes and Prevention
Legal and Financial Information for Patients
LGBT Resources
NCI Resources
Global Resources
Cancer Resource List
Resources for Young Adults
OncoLink Media Library
OncoLink TV
Book, Music and Video Reviews
Ask the Experts
Brown Bag Chat
Tracy's Corner
About OncoLink
About OncoLink
Giving to OncoLink
Contact Information
Usage Policy
Editorial Board
How to Partner with OncoLink
Link to OncoLink
Mission Statement
